Literature DB >> 23992293

Efficacy of black cohosh (Cimicifuga racemosa) medicines for treatment of menopausal symptoms - comments on major statements of the Cochrane Collaboration report 2012 "black cohosh (Cimicifuga spp.) for menopausal symptoms (review)".

André-M Beer1, Rüdiger Osmers, Jörg Schnitker, Wenpei Bai, Alfred O Mueck, Harald Meden.   

Abstract

Menopausal symptoms management with high-quality plant extracts from Actaea (Cimicifuga. racemosa rootstock is well-established. Efficacy and safety are supported by research and clinical trials since several decades and backed up by official monographs. However, the recent published Cochrane review on black cohosh neglects major evidence for beneficial effects. The authors' negative conclusions are questionable and call for reply and clarification. Our careful reconsideration of all appropriate placebo-controlled clinical studies reveals a standardized mean difference of 0.385 in favor of black cohosh (p < 0.0001).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23992293     DOI: 10.3109/09513590.2013.831836

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  9 in total

1.  Motivations for Botanical Use by Socioeconomically Diverse, Urban Adults: Does Evidence Support Motivation?

Authors:  Grace F Duffy; Emily Stave Shupe; Marie Fanelli Kuczmarski; Alan B Zonderman; Michele K Evans
Journal:  J Altern Complement Med       Date:  2017-02-16       Impact factor: 2.579

Review 2.  Ethnobotany, Phytochemistry, Traditional and Modern Uses of Actaea racemosa L. (Black cohosh): A Review.

Authors:  Sofia Salari; Mohammad Sadegh Amiri; Mahin Ramezani; Ali Tafazoli Moghadam; Sepideh Elyasi; Amirhossein Sahebkar; Seyed Ahmad Emami
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Effect of Isopropanolic Cimicifuga racemosa Extract on Uterine Fibroids in Comparison with Tibolone among Patients of a Recent Randomized, Double Blind, Parallel-Controlled Study in Chinese Women with Menopausal Symptoms.

Authors:  Sisi Xi; Eckehard Liske; Shuyu Wang; Jianli Liu; Zhonglan Zhang; Li Geng; Lina Hu; Chunfeng Jiao; Shurong Zheng; Hans-Heinrich Henneicke-von Zepelin; Wenpei Bai
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-02       Impact factor: 2.629

4.  A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients.

Authors:  Juergen Drewe; Kathleen A Bucher; Catherine Zahner
Journal:  Springerplus       Date:  2015-02-10

5.  Role of the ER/NO/cGMP Signaling Pathway in the Promotion of Osteogenic Differentiation of Rat Bone Marrow Mesenchymal Stem Cells by Actaea racemosa Extract.

Authors:  Shenlan Yang; Yanping Zhou; Bo Shuai; Rui Zhu; Wei Xu; Yanran Wu; Danfang Deng; Yingying Luo
Journal:  Evid Based Complement Alternat Med       Date:  2016-11-15       Impact factor: 2.629

Review 6.  60 years of Cimicifuga racemosa medicinal products : Clinical research milestones, current study findings and current development.

Authors:  Hans-Heinrich Henneicke-von Zepelin
Journal:  Wien Med Wochenschr       Date:  2017-02-02

Review 7.  An interpretive review of consensus statements on clinical guideline development and their application in the field of traditional and complementary medicine.

Authors:  Jennifer Hunter; Matthew Leach; Lesley Braun; Alan Bensoussan
Journal:  BMC Complement Altern Med       Date:  2017-02-17       Impact factor: 3.659

8.  Effect of CIMicifuga racemosa on metaBOLIC parameters in women with menopausal symptoms: a retrospective observational study (CIMBOLIC).

Authors:  Lena Friederichsen; Sabine Nebel; Catherine Zahner; Lukas Bütikofer; Petra Stute
Journal:  Arch Gynecol Obstet       Date:  2019-11-16       Impact factor: 2.344

9.  Effects of remifemin treatment on bone integrity and remodeling in rats with ovariectomy-induced osteoporosis.

Authors:  Guangxia Cui; Huijie Leng; Ke Wang; Jianwei Wang; Sainan Zhu; Jing Jia; Xing Chen; Weiguang Zhang; Lihua Qin; Wenpei Bai
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.